The Vanguard Group's Position on Avadel Pharmaceuticals

The Vanguard Group, Inc. has disclosed its interest in Avadel Pharmaceuticals plc as per Irish Takeover Panel Rules. As of November 26, 2025, Vanguard holds 5,577,577 US$0.01 ordinary shares, representing 5.73% of Avadel's relevant securities. This establishes Vanguard as a significant stakeholder, as the disclosure threshold is 1% or more of the company's shares.

During recent transactions, Vanguard purchased 1,306 shares and sold 537 shares, both at $21.40 per share. No cash-settled derivatives or stock-settled derivatives, such as options relating to Avadel, have been reported by Vanguard. Additionally, the company states that there are no indemnity or option arrangements concerning Avadel shares.

This position disclosure reflects Vanguard's compliance with regulatory requirements, while providing insight into their stake in Avadel Pharmaceuticals.